Cellebrite DI Sees Unusually High Options Volume (NASDAQ:CLBT)

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 20,138 call options on the stock. This represents an increase of 2,374% compared to the average daily volume of 814 call options.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, insider Thomas Hogan sold 25,299 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $11.29, for a total transaction of $285,625.71. Following the transaction, the insider directly owned 765,249 shares in the company, valued at $8,639,661.21. This represents a 3.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO David Gee sold 4,323 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the completion of the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This trade represents a 3.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 56,516 shares of company stock valued at $636,660. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently bought and sold shares of CLBT. Nine Ten Capital Management LLC boosted its holdings in shares of Cellebrite DI by 19.8% in the 2nd quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock valued at $60,251,000 after acquiring an additional 682,933 shares during the last quarter. Wellington Management Group LLP lifted its position in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after purchasing an additional 1,475,579 shares during the period. Renaissance Technologies LLC boosted its holdings in Cellebrite DI by 14.7% in the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Cellebrite DI by 33.9% in the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares during the last quarter. Finally, Weiss Asset Management LP boosted its holdings in Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $12.64 on Wednesday. Cellebrite DI has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The firm has a market capitalization of $3.15 billion, a PE ratio of 57.46, a P/E/G ratio of 1.95 and a beta of 1.06. The stock’s 50-day simple moving average is $11.61 and its 200-day simple moving average is $13.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. decreased their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 27th. Lake Street Capital lowered their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, DA Davidson restated a “buy” rating and set a $15.00 price target on shares of Cellebrite DI in a research note on Tuesday, September 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average target price of $16.70.

Get Our Latest Stock Analysis on CLBT

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

See Also

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.